We claim:

1. A compound of formula I,



(I)

wherein

one of J_1 and J_2 is N, and the other is N-Q- R^0;

R^0 is 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R8,

2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl selected from the group consisting of benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) halogen,

2) $-NO_2$,

3) -CN,

4) $-C(O)-NH_2$,

5) -OH,

6) $-NH_2$,

7) $-O-CF_3$

8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by halogen or $-O-(C_1-C_8)$-alkyl,

9) $-(C_1-C_8)$-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri-substituted independently of one another by halogen, NH_2, -OH or methoxy,

10) $-O-(C_1-C_8)$-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2, -OH or methoxy,

11) $-SO_2-CH_3$ or

12) $-SO_2-CF_3$,

provided that when R^0 is a monocyclic or bicyclic 6- to 14-membered aryl, then R8 is at least one halogen, $-C(O)-NH_2$ or $-O-(C_1-C_8)$-alkyl;

the substructure



in formula I is

a 4-to 8 membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen and is un-substituted or substituted 1, 2, 3, 4, 5 or 6 times by R3 or substituted 1 or 2 times by =O;

Q is a direct bond, $-(C_0-C_2)$-alkylene-$C(O)-NR^{10}$-, $-NR^{10}-C(O)-NR^{10}$-, $-NR^{10}-C(O)$-, $-SO_2$-, $-(C_1-C_6)$-alkylene, $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$-, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$-, $-(CH_2)_m-S-(CH_2)_n$-, $-(CH_2)_m-C(O)-(CH_2)_n$-, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$-, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$-, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$-, $-(CH_2)_m-CH(OH)-(CH_2)_n$-, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n$-, $-(C_2-C_3)$-alkylene-O-(C_0-C_3)-alkylene-, $-(C_2-C_3)$-alkylene-S(O)-, $-(C_2-C_3)$-alkylene-$S(O)_2$-, $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n$-, $-(C_2-C_3)$-alkylene-$S(O)_2-NH-(R^{10})$-, $-(C_2-C_3)$-alkylene-$N(R^{10})$- or $-(C_0-C_3)$-alkylene-$C(O)-O-(CH_2)_m$- ,

wherein -$(CH_2)_m$- or -$(CH_2)_n$- are alkylene that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH_2 or -OH, or -$(C_3$-$C_6)$-cycloalkylene, that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH_2 or -OH;

R^1 is hydrogen, -$(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, -$(C_1$-$C_3)$-alkylene-C(O)-NH- R^0, -$(C_1$-$C_3)$-alkylene-C(O)-O-R^{15}, a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R8, a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, -$(C_1$-$C_3)$-perfluoroalkylene, -$(C_1$-$C_3)$-alkylene-S(O)-$(C_1$-$C_4)$-alkyl, -$(C_1$-$C_3)$-alkylene-$S(O)_2$-$(C_1$-$C_3)$-alkyl, -$(C_1$-$C_3)$-alkylene-$S(O)_2$-N($R^{4'}$)-$R^{5'}$, -$(C_1$-$C_3)$-alkylene-O-$(C_1$-$C_4)$-alkyl, -$(C_0$-$C_3)$-alkylene-$(C_3$-$C_8)$-cycloalkyl, or -$(C_0$-$C_3)$-alkylene-het, wherein the het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

$R^{4'}$ and $R^{5'}$ are independent of one another are identical or different and are hydrogen or -$(C_1$-$C_4)$-alkyl,

R^2 is a direct bond or -$(C_1$-$C_4)$-alkylene, or

R^1 and R^3 together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1-N-R^2-V form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is halogen, -OH, =O, -$(C_1$-$C_8)$-alkyl, -$(C_1$-$C_4)$-alkoxy, -NO_2, -C(O)-OH, -CN, -NH_2, -C(O)-O-$(C_1$-$C_4)$-alkyl, -$(C_0$-$C_8)$-alkyl-SO_2-$(C_1$-$C_4)$-alkyl, -$(C_0$-$C_8)$-alkyl-SO_2-$(C_1$-$C_3)$-perfluoroalkyl, -$(C_0$-$C_8)$-alkyl-SO_2-N(R^{18})-R^{21},

-C(O)-NH-(C_1-C_8)-alkyl, -C(O)-N-[(C_1-C_8)-alkyl]$_2$, -NR^{18}-C(O)-NH-(C_1-C_8)-alkyl, -C(O)-NH_2, –S-R^{18}, or –NR^{18}-C(O)-NH-[(C_1-C_8)-alkyl]$_2$,

wherein R^{18} and R^{21} are independently from each other hydrogen, -(C_1-C_3)-perfluoroalkyl or –(C_1-C_6)-alkyl;

V is 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

2) a 6- to14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

G is a direct bond, -$(CH_2)_m$-NR^{10}-SO_2-NR^{10}-$(CH_2)_n$-, -$(CH_2)_m$-CH(OH)-$(CH_2)_n$-, -$(CH_2)_m$-, -$(CH_2)_m$-O-$(CH_2)_n$-, -$(CH_2)_m$-C(O)-NR^{10}-$(CH_2)_n$-, -(CH_2)-SO_2-$(CH_2)_n$-, -$(CH_2)_m$-NR^{10}-C(O)-NR^{10}-$(CH_2)_n$-, -$(CH_2)_m$-NR^{10}-C(O)-$(CH_2)_n$-, -$(CH_2)_m$-C(O)-$(CH_2)_n$-, -(CH_2)-S-$(CH_2)_n$-, -$(CH_2)_m$-SO_2-NR^{10}-$(CH_2)_n$-, -$(CH_2)_m$-NR^{10}-SO_2-$(CH_2)_n$-, -$(CH_2)_m$-NR^{10}-, -$(CH_2)_m$-O-C(O)-NR^{10}-$(CH_2)_n$- or –$(CH_2)_m$-NR^{10}-C(O)-O-$(CH_2)_n$-;

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;

M is 1) hydrogen,

2) -(C_1-C_8)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) -C(O)-N(R11)-R12,

4) -$(CH_2)_m$-NR^{10},

5) a 6- to14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

7) -(C_3-C_8)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 is 1) hydrogen,

2) halogen,

3) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) -(C_1-C_3)-perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) -(C_0-C_4)-alkylene-O-R19,

7) -NO_2,

8) -CN,

9) -SO_s-R^{11}, wherein s is 1 or 2,

10) -SO_t-N(R^{11})-R^{12}, wherein t is 1 or 2,

11) -(C_0-C_4)-alkylene-C(O)-R^{11},

12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},

13) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{12},

14) -(C_0-C_4)-alkylene-N(R^{11})-R^{12},

15) -NR^{10}-SO_2-R^{10},

16) -S-R^{10},

17) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) –(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

21) -(C_0-C_4)-alkylene-(C_6-C_{14})-aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R13,

22) -(C_0-C_4)-alkylene-(C_4-C_{15})-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13

23) -(C_0-C_4)-alkylene-(C_3-C_8)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

24) -(C_0-C_4)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

25) -(C_0-C_4)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-O-(C_0-C_4)-alkyl,

26) -SO_w-N(R^{11})-R^{13}, wherein w is 1 or 2,

27) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{13},

28) -(C_0-C_4)-alkylene-N(R^{11})-R^{13}, or

29) a residue selected from the group consisting of



and

wherein Me is methyl;

R19 is a) hydrogen,

b) -(C_1-C_4)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

d) $-CF_3$, or

e) $-CHF_2$, or

two -OR19 residues and adjacent atoms through which they are attached form together with the atoms which they are attached to a 5- or 6- membered ring, which is unsubstituted or substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,
2) $-(C_1\text{-}C_6)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
3) $-(C_0\text{-}C_6)$-alkyl-$(C_3\text{-}C_8)$-cycloalkyl,
4) $-SO_t\text{-}R^{10}$, wherein t is 1 or 2,
5) $-(C_0\text{-}C_6)$-alkyl-$(C_6\text{-}C_{14})$-aryl, wherein the alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
6) $-(C_1\text{-}C_3)$-perfluoroalkyl,
7) $-O\text{-}R^{17}$, or
8) $-(C_0\text{-}C_6)$-alkyl-$(C_4\text{-}C_{15})$-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is halogen, $-NO_2$, -CN, =O, -OH, $-CF_3$, $-C(O)\text{-}O\text{-}R^{10}$, $-C(O)\text{-}N(R^{10})\text{-}R^{20}$, $-N(R^{10})\text{-}R^{20}$, $-(C_3\text{-}C_8)$-cycloalkyl, $-(C_0\text{-}C_3)$-alkylene-$O\text{-}R^{10}$, $-Si\text{-}(CH_3)_3$, $-N(R^{10})\text{-}S(O)_u\text{-}R^{10}$, wherein u is 1 or 2, $-S\text{-}R^{10}$, $-SO_r\text{-}R^{10}$, wherein r is 1 or 2, $-S(O)_v\text{-}N(R^{10})\text{-}R^{20}$, wherein v is 1 or 2, $-C(O)\text{-}R^{10}$, $-(C_1\text{-}C_8)$-alkyl, $-(C_1\text{-}C_8)$-alkoxy, phenyl, phenyloxy, $-O\text{-}CF_3$, $-(C_0\text{-}C_4)$-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, $-(C_1\text{-}C_4)$-alkoxy-phenyl, $-(C_0\text{-}C_4)$-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, $-(C_1\text{-}C_3)$-perfluoroalkyl,

-O-R15, -NH-C(O)-NH-R^{10}, -NH-C(O)-O-R^{10}, or a residue from the group consisting of



and ,

wherein Me is methyl;

R^{10} and R^{20} are independently of one another hydrogen, -(C_1-C_6)-alkyl, -(C_0-C_4)-alkyl-OH, -(C_0-C_4)-alkyl-O-(C_1-C_4)-alkyl or -(C_1-C_3)-perfluoroalkyl;

R15 and R16 are independently of one another hydrogen, -(C_1-C_6)-alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R^{10}; and

R17 is -(C_1-C_6)-alkyl, -(C_1-C_6)-alkyl-OH, -(C_1-C_6)-alkyl-O-(C_1-C_6)-alkyl, -(C_3-C_8)-cycloalkyl, -(C_1-C_6)-alkyl-O-(C_1-C_8)-alkyl-(C_3-C_8)-cycloalkyl, -(C_1-C_6)-alkyl-(C_3-C_8)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by –OH, -O-(C_1-C_4)-alkyl or R^{10};

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically tolerable salt thereof.

2. The compound according to claim 1, wherein

substructure D is a 5-to 6 membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen and is substituted 1, 2, 3, 4, 5 or 6 times by R3;

R3 as 25) is -(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-O-(C_0-C_3)-alkyl; and

R^{10} and R^{20} are independently of one another hydrogen, -(C_1-C_6)-alkyl or -(C_1-C_3)-perfluoroalkyl;

3. The compound according to claim 1, wherein

R^0 as 1) is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or

3) is acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl,

each of which is unsubstituted or mono-, di- or trisubstituted
independently of one another by R8, and
which is additionally substituted by a heterocyclyl selected from the group consisting of acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,
wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

substructure D is a residue selected from the group consisting of azetidine, azetine, azocane, azocane-2-one, cyclobutyl, cyclooctane, cyclooctene, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole,

isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolan, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, [1,4]oxazocane, [1,3]oxazocan-2-one, oxetan, oxocane, oxocan-2-one, piperazine, piperidine, phenyl, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thietan, thiocane, thiocane-1,1-dioxide, thiocane-1-oxide, thiocan-2-one, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole and 1,2,4-triazole, and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R3;

R^1 as a monocyclic or bicyclic 6- to 14-membered aryl is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or

-(C_0-C_3)-alkylene-het, wherein the het is a residue selected from the group concsisting of azepine, azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole and 1,2,4-triazole, wherein the het is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1 and R3 together with the atoms to which they are bonded form azocane, azocane-2-one, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1-N-R^2-V form azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

V is 2) phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R14, or

3) acridinyl, azaindole (1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl,

each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

M is 1) hydrogen,

2) -(C_1-C_8)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) -C(O)-N(R11)-R12,

4) -$(CH_2)_m$-NR^{10},

5) -(C_6-C_{14})-aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

6) -(C_4-C_{15})-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) -(C_3-C_8)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 as 25) is -(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-O-(C_0-C_3)-alkyl,

two -OR19 residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, which is substituted one, two, three or four times by R13;

R11 and R12 together with the nitrogen atom to which they are bonded may form azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; and

R15 and R16 are independently of one another hydrogen, -(C_1-C_6)-alkyl, or together with the carbon atom to which they are bonded form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10}.

4. The compound according to claim 1, wherein

R^0 as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or

3) is azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, 2-furyl, 3-furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinolinyl, quinazolinyl, quinoxalinyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl,
each of which is additionally substituted by a heterocyclyl selected from the group consisting of acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl,

1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,
wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 as 1) is F, Cl, or Br;

substructure D is a residue selected from the group consisting of phenyl, pyridyl, pyridyl-N-oxide pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, and pyrazinyl. and is unsubstituted or substituted 1, 2, 3 or 4 times by R3;

Q is a direct bond, -(C_0 –C_2)-alkylene-C(O)-NR^{10}-, -NR^{10}-C(O)-NR^{10}-, -NR^{10}-C(O)-, -SO_2- or -(C_1-C_6)-alkylene or -(C_0-C_3)-alkylene-C(O)-O-(C_0-C_2)-alkylene;

R^1 is hydrogen, -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, -(C_1-C_3)-alkylene-C(O)-NH- R^0, -(C_1-C_3)-alkylene-C(O)-O- R^{15}, -(C_1-C_3)-perfluoroalkylene, -(C_1-C_3)-alkylene-S(O)-(C_1-C_4)-alkyl, -(C_1-C_3)-alkylene-S(O)$_2$-(C_1-C_3)-alkyl, -(C_1-C_3)-alkylene-S(O)$_2$-N($R^{4'}$)-$R^{5'}$, -(C_1-C_3)-alkylene-O-(C_1-C_4)-alkyl, -(C_0-C_3)-alkylene-(C_3-C_8)-cycloalkyl, or -(C_0-C_3)-alkylene-het, wherein the het is azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1-N-R^2-V form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine,

isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

3) azaindole (1H-pyrrolopyridine), azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

M is 1) hydrogen,

2) -(C_1-C_8)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) -C(O)-N(R11)-R12,

4) -$(CH_2)_m$-NR^{10},

5) phenyl or naphthyl, wherein the phenyl or naphthyl are unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

6) (C_4-C_{15})-heterocyclyl, wherein the heterocyclyl is selected from the group consisting of azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole,

thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole and 1,2,4-triazole, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) -(C_3-C_8)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 is 1) hydrogen,

2) halogen,

3) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) -(C_1-C_3)-perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) -(C_0-C_4)-alkylene-O-R19,

8) -CN,

9) -SO_s-R^{11}, wherein s is 1 or 2,

10) -SO_t-N(R^{11})-R^{12}, wherein t is 1 or 2,

11) -(C_0-C_4)-alkylene-C(O)-R^{11},

12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},

13) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{12},

14) -(C_0-C_4)-alkylene-N(R^{11})-R^{12},

15) -NR^{10}-SO_2-R^{10},

17) -(C_0-C_2)-alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) –(C_0-C_2)-alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

21) -(C_0-C_4)-alkylene-(C_6-C_{14})-aryl, wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by R13,

22) -(C_0-C_4)-alkylene-(C_4-C_{15})-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

23) -(C_0-C_4)-alkylene-(C_3-C_8)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

24) -(C_0-C_4)-alkylene-het, wherein the het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

25) -(C_0-C_3)-alkylene-O-CH_2-CF_2-CH_2-O-(C_0-C_3)-alkyl, -(C_0-C_3)-alkylene-O-CH_2-CF_2-CF_2-CH_2-O-(C_0-C_3)-alkyl, or -(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-OH,

26) -SO_w-N(R^{11})-R^{13}, wherein w is 1 or 2,

27) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{13},

28) -(C_0-C_4)-alkylene-N(R^{11})-R^{13}, or

29) a residue selected from the group consisting of



and

wherein Me is methyl;

two -OR19 residues and adjacent atoms through which thay are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,

2) -(C_1-C_6)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

5) -(C_0-C_6)-alkyl-(C_6-C_{14})-aryl, wherein the alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13,

7) -O-R^{17}, or

8) -(C_0-C_6)-alkyl-(C_4-C_{15})-heterocyclyl, wherein the alkyl and heterocyclyl are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is fluorine, chlorine, bromine, iodine, -NO_2, -CN, =O, -OH, -CF_3, -C(O)-O-R^{10}, -C(O)-N(R^{10})-R^{20}, -N(R^{10})-R^{20}, -(C_0-C_3)-alkylene-O-R^{10}, -Si-(CH_3)$_3$, -N(R^{10})-S(O)$_2$-R^{10}, -S-R^{10}, -SO_2-R^{10}, -S(O)$_2$-N(R^{10})-R^{20}, -C(O)-R^{10}, -(C_1-C_8)-alkyl, -(C_1-C_8)-alkoxy, phenyl, phenyloxy-, -O-CF_3, -(C_1-C_3)-perfluoroalkyl, -(C_0-C_4)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C_1-C_4)-alkoxy-phenyl, -(C_0-C_4)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -O-R15, -NH-C(O)-NH-R^{10}, -NH-C(O)-O-R^{10}, or a residue selected from the group consisting of





and  ,

wherein Me is methyl; and

R15 and R16 are independently of one another hydrogen, -(C_1-C_6)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10}.

5. The compound according to claim 1, wherein

R0 as 1) is phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) a heterocyclyl selected from the group consisting of pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,
and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) F, Cl, Br or I,

4) -C(O)-NH_2,

9) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or

10) –O-(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,

provided that R8 is at least one halogen, -C(O)-NH_2 or –O-(C_1-C_8)-alkyl;

substructure D is a residue selected from the group consisting of phenyl, pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl and pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3;

Q is a direct bond, -C(O)-, -SO_2- or -(C_1-C_6)-alkylene, -(C_0–C_2)-alkylene-C(O)-NR^{10}- or -(C_0-C_3)-alkylene-C(O)-O-(C_0-C_2)-alkylene;

R^1 is hydrogen, -(C_1-C_2)-alkyl, -(C_1-C_3)-alkylene-C(O)-NH- R^0, -(C_1-C_3)-perfluoroalkylene, -(C_1-C_3)-alkylene-C(O)-O-R^{15}, -(C_1-C_3)-alkylene-S(O)$_2$-(C_1-C_3)-alkyl or -(C_1-C_3)-alkylene-S(O)$_2$-N($R^{4'}$)-$R^{5'}$,

R^2 is a direct bond or -(C_1-C_2)-alkylene, or

R^1-N-R^2-V form azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, eachof which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluorine, chlorine, -OH, =O, -(C_1-C_8)-alkyl, -C(O)-OH, -CN, -NH_2, -C(O)-O-(C_1-C_4)-alkyl, -C(O)-NH-(C_1-C_8)-alkyl, -C(O)-N-[(C_1-C_8)-alkyl]$_2$, -C(O)-NH_2 or –N(R^{18})-R^{21}, wherein R^{18} and R^{21} are independently from each other hydrogen, -(C_1-C_3)-perfluoroalkyl or –(C_1-C_4)-alkyl;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

3) a cyclic residue selected from the group consisting of azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, oxazole, isoxazole, 2-isoxazoline,

isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine and thiomorpholine,

wherein sthe cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond, $-(CH_2)_m-$, or $-(CH_2)_m-NR^{10}-$;

m is zero, 1, 2, 3 or 4;

M is

1) hydrogen,

2) $-(C_1-C_6)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) $-C(O)-N(R^{11})-R^{12}$, or

6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole and 1,2,4-triazole, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) (C_3-C_6)-cycloalkyl;

R3 is

1) hydrogen,

2) halogen,

3) $-(C_1-C_4)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) $-(C_1-C_3)$-perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) $-(C_0-C_4)$-alkylene-O-R19,

8) -CN,

8) $-NR^{10}-SO_2-R^{10}$,

9) $-SO_s-R^{11}$, wherein s is 1 or 2,

10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,

11) $-(C_0-C_4)$-alkylene-C(O)-R^{11},

12) $-(C_0-C_4)$-alkylene-C(O)-O-R^{11},

13) $-(C_0-C_4)$-alkylene-C(O)-$N(R^{11})-R^{12}$,

14) $-(C_0-C_4)$-alkylene-$N(R^{11})-R^{12}$,

17) $-(C_0-C_2)$alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) $-(C_0-C_2)$alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

25) $-(C_0-C_3)$-alkylene-O-$CH_2-CF_2-CH_2$-O-(C_0-C_3)-alkyl,

$-(C_0-C_3)$-alkylene-O-$CH_2-CF_2-CF_2-CH_2$-O-(C_0-C_3)-alkyl, or

$-(C_0-C_3)$-alkylene-O-$CH_2-(C_1-C_3)$-perfluoroalkylene-CH_2-OH,

26) $-SO_w-N(R^{11})-R^{13}$, wherein w is 1 or 2,

27) $-(C_0-C_4)$-alkylene-C(O)-$N(R^{11})-R^{13}$,

28) $-(C_0-C_4)$-alkylene-$N(R^{11})-R^{13}$, or

29) a residue selected from the group consisting of



and

wherein Me is methyl;

two -OR19 residues and adjacent atoms through which they are attached may form a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R13;

R^{11} and R^{12} together with the nitrogen atom to which they are bonded may form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, rach of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is fluorine, chlorine, $-NO_2$, -CN, =O, -OH, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_0-C_3)$-alkylene-$O-R^{10}$, $-Si-(CH_3)_3$, $-N(R^{10})-S(O)_2-R^{10}$, $-S-R^{10}$, $-SO_2-R^{10}$, $-S(O)_2-N(R^{10})-R^{20}$, $-C(O)-R^{10}$, $-(C_1-C_8)$-alkyl, $-(C_1-C_8)$-alkoxy, phenyl, phenyloxy-, $-O-CF_3$, $-(C_1-C_3)$-perfluoroalkyl, $-NH-C(O)-NH-R^{10}$, $-(C_0-C_4)$-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, $-(C_1-C_4)$-alkoxy-phenyl, $-(C_0-C_4)$-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -O-R15, $-NH-C(O)-O-R^{10}$, or a residue from the group consisting of



and,

wherein Me is methyl; and

R15 and R16 are independently of one another hydrogen, $-(C_1-C_6)$-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10}

6. The compound according to claim 1, wherein

R0 as 1) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) a heterocyclyl selected from of the group consisting of pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) F, Cl, Br, or I,

4) $-C(O)-NH_2$,

9) $-(C_1-C_4)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or

10) $-O-(C_1-C_4)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,

provided that R8 is at least one halogen, $-C(O)-NH_2$ or $-O-(C_1-C_8)$-alkyl;

substructure D is a residue selected from the group consisting of phenyl, pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl and pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R^3;

Q is a direct bond, -C(O)-, $-SO_2-$ -C(O)-O-methylene, $-(C_1-C_6)$-alkylen or $-(C_0-C_2)$-alkylen-C(O)-NR^{10}-;

R^1 is hydrogen or $-(C_1-C_2)$-alkyl,

R^2 is a direct bond or $-(C_1-C_2)$-alkylen, or

R^1-N-R^2-V form piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine,

each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluoro, chlorine, -(C_1-C_4)-alkyl or -NH_2;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

3) a cyclic residue selected from the group consisting of azaindolyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, 1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole and 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond, -$(CH_2)_m$-, or -$(CH_2)_m$-NR^{10}-;

m is zero, 1, 2, 3 or 4;

M is 1) hydrogen,

2) -(C_1-C_6)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

3) -C(O)-N(R^{11})-R^{12}, or

6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of 1,4-diazepane, ketomorpholine, thiophene, pyridazone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, thiadiazole or thiomorpholine, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) (C_3-C_6)-cycloalkyl;

R3 is

1) hydrogen,

2) halogen,

3) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) -(C_1-C_3)-perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) -(C_0-C_4)-alkylene-O-R19,

8) -CN,

8) $-NR^{10}-SO_2-R^{10}$,

9) $-SO_s-R^{11}$, wherein s is 1 or 2,

10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,

11) -(C_0-C_4)-alkylene-C(O)-R^{11},

12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},

13) -(C_0-C_4)-alkylene-C(O)-$N(R^{11})-R^{12}$,

14) -(C_0-C_4)-alkylene-$N(R^{11})-R^{12}$,

17) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) –(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

26) -(C_0-C_3)-alkylene-O-CH_2-CF_2-CH_2-O-(C_0-C_3)-alkyl,
-(C_0-C_3)-alkylene-O-CH_2-CF_2-CF_2-CH_2-O-(C_0-C_3)-alkyl, or
-(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-OH,

26) $-SO_w-N(R^{11})-R^{13}$, wherein w is 1 or 2,

27) -(C_0-C_4)-alkylene-C(O)-$N(R^{11})-R^{13}$,

28) -(C_0-C_4)-alkylene-$N(R^{11})-R^{13}$, or

29) a residue selected from the group consisting of



and

wherein Me is methyl;

R19 is a) hydrogen,

b) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

d) $-CF_3$, or

e) $-CHF_2$;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,

2) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

3) -(C_0-C_6)-alkyl-(C_3-C_6)-cycloalkyl,

7) $-O-R^{17}$, or

8) -(C_0-C_6)-alkyl-(C_4-C_{15})-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine;

R13 is fluorine, -CN, =O, -OH, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_6)$-cycloalkyl, $-(C_0-C_3)$-alkylene-O-R^{10}, $-Si-(CH_3)_3$, $-S-R^{10}$, $-SO_2-R^{10}$, $-(C_1-C_3)$-perfluoroalkyl, or a residue selected from the group consisting of



and,

wherein Me is methyl;

R^{10} and R^{20} are independently of one another hydrogen, $-(C_1-C_4)$-alkyl or $-(C_1-C_3)$-perfluoroalkyl; and

R^{15} and R^{16} are independently of one another hydrogen, $-(C_1-C_4)$-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10}.

7. The compound according to claim 1, wherein

R0 is 1) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R8,

2) pyridyl, wherein the pyridyl is unsubstituted or mono- or disubstituted independently of one another by R8, or

3) a heterocyclyl selected from the group consisting of thienyl, thiadiazolyl, isoxazolyl and thiazolyl, wherein the heterocyclyl is substituted by thienyl, 2-thienyl and 3-thienyl, each of which is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is F, Cl, Br, $-OCH_3$, $-C(O)-NH_2$ or $-O-CF_3$;

substructure D is a residue selected from the group consisting of phenyl, pyridyl, pyridyl-N-oxide, pyrrolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl and pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3,;

Q is a direct bond, -C(O)-, -SO_2-, -C(O)-O-methylene, -CH_2-C(O)-NH-, methylene or ethylene;

R^1 is hydrogen,

R^2 is a direct bond or methylene, or

R^1-N-R^2-V form azetidine, pyrrolidine, piperidine or piperazine;

R14 is fluorine, chlorine, methyl, ethyl, =O, -SO_2-CH_3 or -NH_2;

V is 2) phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R14, or

3) azaindolyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyrane, each of which is unsubstituted or mono- or disubstituted independently of one another by R14;

G is a direct bond, -$(CH_2)_m$-, -C(O)- or -$(CH_2)_m$-NR^{10}-;

m is zero, 1 or 2;

M is 1) hydrogen,

2) (C_2-C_4)-alkyl, wherein the alkyl is unsubstituted or mono- or disubstituted independently of one another by R14, or

6) azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]Oxazepanyl, piperidinyl, phenyl, piperidonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolidinyl, 1,4,5,6-tetrahydro-pyridazinyl, or tetrahydropyranyl, each of which is unsubstituted or mono- or disubstituted independently of one another by R14;

R3 is

1) hydrogen,

2) F or Cl,,

3) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

4) -(C_1-C_3)-perfluoroalkyl,

5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

6) -(C_0-C_2)-alkylene-O-R19,

8) -CN,

9) -SO_s-R^{11}, wherein s is 1 or 2,

10) -SO_t-$N(R^{11})$-R^{12}, wherein t is 1 or 2,

11) -(C_0-C_4)-alkylene-C(O)-R^{11},

12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},

13) -(C_0-C_4)-alkylene-C(O)-$N(R^{11})$-R^{12},

14) -(C_0-C_4)-alkylene-$N(R^{11})$-R^{12},

15) -NR^{10}-SO_2-R^{10},

17) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) –(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

27) -(C_0-C_4)-alkylene-C(O)-$N(R^{11})$-R^{13} or

29) a residue selected from the group consisting of



and

wherein Me is methyl;

R19 is a) hydrogen,

b) -(C_1-C_4)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

d) $-CF_3$, or

e) $-CHF_2$;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,

2) $-(C_1-C_4)$-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

3) $-(C_0-C_6)$-alkyl-(C_3-C_6)-cycloalkyl,

7) $-O-R^{17}$, or

8) $-(C_0-C_6)$-alkyl-(C_6-C_{15})-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, imidazolidine, morpholine, 4,5-dihydro-[1,2,4]oxadiazole, -[1,3]dioxole, (1,4)-oxazepane or pyrrolidine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, -CN, =O, -OH, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_6)$-cycloalkyl, $-(C_0-C_3)$-alkylene-$O-R^{10}$, $-Si-(CH_3)_3$, $-S-R^{10}$, $-SO_2-R^{10}$, $-SO_2-NH$, $-(C_1-C_3)$-perfluoroalkyl, $-(C_1-C_3)$-alkyl, or a residue selected from the group consisting of



and

,

wherein Me is methyl;

R^{10} and R^{20} are independently of one another hydrogen, $-(C_1-C_4)$-alkyl or $-(C_1-C_3)$-perfluoroalkyl; and

R^{15} and R^{16} are independently of one another hydrogen, $-(C_1-C_4)$-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10}.

8. The compound according to claim 1, wherein J_1 is N and J_2 is N-Q-R^0.

9. The compound according to claim 1, wherein J_2 is N and J_1 is N-Q-R^0.

10. The compound according to claim 1, wherein the compound is
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid methyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-6-carboxylic acid methyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-7-carboxylic acid methyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-7-carboxylic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-6-carboxylic acid,
Indazole-1,3-dicarboxylic acid 1-[(5-chloro-pyridin-2-yl)-amide] 3-[(1-isopropyl- piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-cyano-1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
5-(Azetidine-1-carbonyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole- 3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-methanesulfonyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-sulfamoyl-ethyl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2-morpholin-4-yl-ethyl)-amide],

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-trimethylsilanylmethyl-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5-[bis-(2-hydroxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5- [(2-hydroxy-ethyl)-methyl-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carbonyl]-amino}-acetic acid ethyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5-[(2,2-difluoro-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5-carbamoylmethyl-amide 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5- [(2-hydroxy-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-{[2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide},
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 5- [(2-hydroxy-1-hydroxymethyl-1-methyl-ethyl)-amide] 3-[(1-isopropyl-piperidin-4-yl)- amide] ,
{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carbonyl]-amino}-acetic acid,
1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carbonyl]-(2S)-azetidine-2-carboxylic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-[(2,2,2-trifluoro-ethyl)-amide],
{[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carbonyl]-methyl-amino}-acetic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid 2-hydroxy-ethyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-([1,4]oxazepane-4-carbonyl)-1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(3-hydroxy-azetidine-1-carbonyl)- 1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3,5-dicarboxylic acid 3- [(1-isopropyl-piperidin-4-yl)-amide] 5-(methoxy-amide),
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid [4- (piperidine-1-carbonyl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4-(pyrrolidine-1-carbonyl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4-(morpholine-4-carbonyl)-phenyl]-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid [4- (morpholine-4-carbonyl)-phenyl]-amide,

1-(1-{1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carbonyl}-piperidin-4-yl)-pyrrolidin-2-one,

N-(5-Chloro-pyridin-2-yl)-2-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidine-1-carbonyl]- indazol-1-yl}-acetamide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4-(2-oxo-pyrrolidin-1-yl)-phenyl]-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid [4-(2-oxo-pyrrolidin-1-yl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid (4-morpholin-4-yl-phenyl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4- (1H-imidazol-4-yl)-phenyl]-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid (4-piperidin-1-yl-phenyl)-amide,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-[4-(3-oxo-morpholin-4-yl)-phenylcarbamoyl]-1H-indazole-5-carboxylic acid methyl ester,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid methyl ester,

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)- 1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,

1-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carbonyl]-azetidine-3-carboxylic acid,
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid [4-(3-oxo-morpholin-4-yl)-phenyl]-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-indazole-3-carboxylic acid [4-(4-oxo-4H-pyridin-1-yl)-phenyl]-amide,
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-1H-indazole-3-carboxylic acid [4-(4-oxo- 4H-pyridin-1-yl)-phenyl]-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid 2-methoxy-ethyl ester,
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-indazole-5-carboxylic acid 2-hydroxy-ethyl ester, or
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-([1,4]oxazepane-4-carbonyl)-1H-indazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide.

11. A process for the preparation of a compound according to claim 1, wherein J_1 is N and J_2 is N-Q-R^0, which comprises condensing a compound of the formula **7** with a compound of the formula $HR^{8'}$ to give a compound of the formula **8** and converting the compound of the formula **8** into a compound of the formula I, wherein J_1 is N and J_2 is N-Q-R^0,



wherein the residue $R^{8'}$ has the donation of -N(R^1)-R^2-V-G-M as indicated in claim 1, but where in $R^{8'}$ functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in –N(R^1)-R^2-V-G-M, and where the residue R^{136} denotes the group –Q-R^o or can denote a group which is subsequently transformed into the group –Q-R^o, and where the group –C(O)-R^{135} can be a carboxylic acid group or derivatives thereof, and where the groups R^3 in the formulae **7** and **8** have the corresponding definitions of R^3 in formula I as defined in claim 1 functional groups in them can also be present in protected form or in the form of precursor groups.

12. A process for the preparation of a compound according to claim 1, wherein J_2 is N and J_1 is N-Q-R^0, which comprises condensing a compound of the formula **9** with a compound of the

formula $HR^{8'}$ to give a compound of the formula **10** and optionally converting the compound of the formula **10** into a compound according of formula I, wherein J_2 is N and J_1 is N-Q-R^0,



wherein the residue $R^{8'}$ has the donation of –N(R^1)-R^2-V-G-M as indicated in claim 1, but where in $R^{8'}$ functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in –N(R^1)-R^2-V-G-M, and where the residue R^{136} denotes the group –Q-R^o or can denote a group which is subsequently transformed into the group –Q-R^o, and where the group –C(O)-R^{135} can be a carboxylic acid group or derivatives thereof, and where the groups R^3 in the formulae **9** and **10** have the corresponding definitions of R^3 in formula Ib as defined in claim 1 or functional groups in them can also be present in protected form or in the form of precursor groups.

13. A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

14. A method for inhibiting factor Xa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

15. A method for inhibiting factor VIIa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

16. A method for influencing blood coagulation in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

17. A method for inhibiting influencing blood fibrinolysis in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

18. A method for treating abnormal thrombus formation, acute myocardial infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure associated

with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory response, fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder, deep vein or proximal vein thrombosis, which can occur following surgery, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.